Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. clinical analysis
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Clinical Analysis Articles & Analysis

63 news found

BC Platforms launches next generation trusted research environment on AWS Marketplace

BC Platforms launches next generation trusted research environment on AWS Marketplace

The update delivers an all-new user interface and enables secure, compliant analysis of complex clinical, real-world, and multi-omics data within a single TRE, simplifying deployment, configuration, and lifecycle management.BC Mosaic is designed to accelerate research by enabling rapid deployment and retirement of study-specific environments, reducing the time, ...

ByBC Platforms


Tethis S.p.A. Collaborates with Weill Cornell Medicine to Advance Cellular Residual Disease Monitoring in Early-Stage Breast Cancer

Tethis S.p.A. Collaborates with Weill Cornell Medicine to Advance Cellular Residual Disease Monitoring in Early-Stage Breast Cancer

It stabilizes the cellular fraction on nanocoated SmartBioSurface® slides for detecting rare cells like CTCs, while plasma is made available for the analysis of cfDNA, cfRNA/miRNA, proteins, metabolites, and exosomes. By processing fresh blood in EDTA tubes shortly after collection, See.d maintains sample integrity and clinical value. ...

ByTethis S.p.A


Medical Equipment Pump Solutions

Medical Equipment Pump Solutions

Medical Equipment Pump Solutions Industry Overview IVD, which stands for in vitro diagnostics, refers to products that conduct testing on samples taken from the human body (such as blood, body fluids, and tissues) outside of the body in order to obtain clinical diagnostic information. The IVD industry is subdivided into various sectors including immunodiagnostics, ...

ByTops Industry & Technology Co.,Ltd.


Kardiolytics’ VCAST Technology Offers Non-Invasive and Safe Solution for Functional Evaluation of Coronary Disease, According to Recent Study in Cardiovascular Engineering and Technology

Kardiolytics’ VCAST Technology Offers Non-Invasive and Safe Solution for Functional Evaluation of Coronary Disease, According to Recent Study in Cardiovascular Engineering and Technology

Our latest publication in Cardiovascular Engineering and Technology showcases the feasibility and functionality of our VCAST technology, a patented, AI-based medical system developed for non-invasive, clinical quantitative and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. ...

ByMedicalgorithmics S.A.


NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. ...

ByBayer AG


Exploring next steps in cancer precision diagnostics using transcriptomics

Exploring next steps in cancer precision diagnostics using transcriptomics

The variation reflects the underlying cause of a cell’s character and thus RNA analysis gives a more accurate view of the state cells are in compared to DNA analysis. ...

ByQlucore AB


Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16 weeks at week 48

Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16 weeks at week 48

Patients were randomized in three different arms and all patients in the aflibercept 8 mg arms were continuously evaluated under stringent, clinically relevant, and patient focused dosing regimen modification (DRM) criteria. 77% of nAMD and 89% of DME patients maintained every 16-week dosing intervals with aflibercept 8 mg at week 48 in the clinical trials. In ...

ByBayer AG


Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure

Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure

The researchers showed that Daxor’s BVA-100 was able to measure intravascular volume overload in heart failure patients – a key metric targeted to successfully manage heart failure. Common surrogate markers and clinical evaluation to assess volume overload in contrast were shown to be ineffective at making a comparative clinically actionable measure, ...

ByDaxor Corporation


Michael Blum joins SeqOne Genomics to head the company’s Research and Development

Michael Blum joins SeqOne Genomics to head the company’s Research and Development

In 2019, he joined Owkin where, for the past three years, he has developed AI-based solutions to optimize clinical trials. At SeqOne, Michael will lead scientific research and the development of new genomic analysis solutions to improve the clinical interpretation and diagnosis of cancer and hereditary diseases. ...

BySeqOne S.A.S.


Lixte Biotechnology announces approval of a phase 1B/2 Randomized Trial of Doxorubicin +/-LB-100 In Advanced Soft Tissue Sarcomas to Be Conducted By the Spanish Sarcoma Group

Lixte Biotechnology announces approval of a phase 1B/2 Randomized Trial of Doxorubicin +/-LB-100 In Advanced Soft Tissue Sarcomas to Be Conducted By the Spanish Sarcoma Group

In animal models, LB-100 has consistently enhanced the anti-tumor activity of doxorubicin without apparent increases in toxicity. The interim analysis of this clinical trial will be done before full accrual is completed to determine whether the study has the possibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin ...

ByLIXTE Biotechnology Holdings, Inc.


CD Genomics RNA-Solutions Platform Now Provides Whole Transcriptome Sequencing Service

CD Genomics RNA-Solutions Platform Now Provides Whole Transcriptome Sequencing Service

Whole transcriptome sequencing allows the analysis of the interactions and co-expression regulatory networks between various RNAs, as well as competing endogenous RNAs (ceRNAs). In addition to exploring competing ceRNA networks, whole transcriptome sequencing has a wide range of applications in clinical research and clinical diagnostics, from ...

ByCD Genomics


FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

LYTGOBI (pronounced “light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI covalently binds to FGFR2 and inhibits the signaling pathway. ...

ByTaiho Oncology, Inc.


SeqOne Genomics announces Portuguese distribution partnership

SeqOne Genomics announces Portuguese distribution partnership

SeqOne Genomics, provider of next-generation genomic analysis solutions for personalized medicine is proud to announce a new strategic partnership with ILC Instrumentos de Laboratório Científicos to facilitate access to its genomic analysis solutions in Portugal. ...

BySeqOne S.A.S.


OncoDNA Announces the Operational Launch of its OncoDEEP Kit for Comprehensive Genomic Profiling of Solid Tumors

OncoDNA Announces the Operational Launch of its OncoDEEP Kit for Comprehensive Genomic Profiling of Solid Tumors

The OncoDEEP Kit integrates both reagents and quality control reporting for sequencing over 600 cancer genes and relevant biomarkers, together with OncoDNA’s data analysis and clinical interpretation tools for the rapid analysis and reporting of a patient’s tumor molecular profile. ...

ByOncoDNA S.A.


Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

(NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that positive results of analytical and clinical studies of Bluejay’s Symphony IL-6 Test were presented at AACC 2022, the leading industry ...

ByBluejay Diagnostics, Inc.


Inspirata Unveils New Partnership at the Association of Pathology Chairs (APC) Annual Meeting 2022

Inspirata Unveils New Partnership at the Association of Pathology Chairs (APC) Annual Meeting 2022

“We are excited to partner with SpIntellx to bring new translational research and clinical spatial analysis tools to the Dynamyx digital pathology platform,” said Mark Lloyd, Founder and Executive Vice President of Inspirata. ...

ByInspirata, Inc


New Data Demonstrates Substantial Reduction of Migraine Days Using Neurolief’s Digital Therapeutics Technology

New Data Demonstrates Substantial Reduction of Migraine Days Using Neurolief’s Digital Therapeutics Technology

Neurolief, a neurotechnology innovator, today announced new data released at the 64th Annual Scientific Meeting hosted by the American Headache Society (June 9-12th, 2022, Denver, CO). The real-world, open-label analysis presents clinically meaningful data on the prevention of migraine, including responder rate, reduction in monthly migraine days and reduction ...

ByNeurolief Ltd.


Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress

Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant preservation of kidney function in LN patients A pooled analysis from the AURA-LV and AURORA 1 studies, also presented at ERA, showed early treatment response to ...

ByAurinia Pharmaceuticals Inc.


Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

(NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces positive top-line safety and efficacy data from its Phase 2 pivotal trial for severe Leukocyte Adhesion Deficiency-I (LAD-I) at the 25th Annual Meeting of the American Society ...

ByRocket Pharmaceuticals, Inc.


VIDA Introduces New AI-Enabled Biomarker Services

VIDA Introduces New AI-Enabled Biomarker Services

(VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. ...

ByVIDA Diagnostics Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT